• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表皮生长因子受体酪氨酸激酶抑制剂相关皮肤不良反应肺癌患者的健康相关生活质量及其与应对方式和自我管理的关系。

The health-related quality of life of lung cancer patients with EGFR-TKI-related skin adverse drug reactions and its relationship with coping style and self-management.

机构信息

The College of Nursing and Health of Zhengzhou University, Zhengzhou, 450001, China.

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

出版信息

Support Care Cancer. 2022 Dec;30(12):9889-9899. doi: 10.1007/s00520-022-07451-2. Epub 2022 Nov 19.

DOI:10.1007/s00520-022-07451-2
PMID:36400979
Abstract

PURPOSE

The status and associated factors of the health-related quality of life of non-small-cell lung cancer (NSCLC) patients under targeted anti-cancer therapy have not been investigated. Self-management and coping style have been proven to be closely related to patients' health-related quality of life. Based on these observations, this study was designed to firstly assess the status of health-related quality of life, and then explore the relationships among coping styles, self-management, and health-related quality of life of NSCLC patients with skin adverse drug reactions under targeted therapy.

METHODS

We performed a cross-sectional study including 536 NSCLC patients with skin adverse drug reactions under targeted therapy in cancer clinics of three hospitals in China between May 2020 and May 2021. Structured questionnaires, including the Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor 18, Cancer Patient Self-management Evaluation Scale, and Medical Coping Modes Questionnaire, were used to collect data. Relationships among coping style, self-management, and health-related quality of life were identified by Pearson correlation analysis and a multiple linear regression algorithm.

RESULTS

The total score of health-related quality of life was 46 ± 12.84 in 536 NSCLC patients with skin adverse drug reactions undergoing targeted therapy. Health-related quality of life was positively correlated with self-management (r = 0.785, P < 0.01) and facing (r = 0.807, P < 0.01) and negatively correlated with yield (r =  - 0.718, P < 0.01), avoidance (r =  - 0.711, P < 0.01), and the severity of skin adverse reactions (r =  - 0.722, P = 0.000). Via multiple linear regression analysis, we identified some significant factors associated with health-related quality of life, including age, education level, combination of medicine, Charlson Comorbidity Index, stages of disease, facing, yield, symptom management, daily activity management, psychological and emotional management, self-efficacy, and self-management (P < 0.05).

CONCLUSIONS

NSCLC patients with skin adverse drug reactions undergoing targeted therapy generally had a compromised health-related quality of life. The critical factors that were associated with the status of health-related quality of life were age, education level, comorbidity, the combinatorial application of drugs, stage of disease, self-management, and coping styles.

摘要

目的

针对接受靶向抗癌治疗的非小细胞肺癌(NSCLC)患者的健康相关生活质量状况及其相关因素,目前尚未开展相关研究。自我管理和应对方式已被证明与患者的健康相关生活质量密切相关。基于这些观察结果,本研究旨在首先评估健康相关生活质量的状况,然后探讨接受靶向治疗的 NSCLC 患者皮肤不良反应的应对方式、自我管理与健康相关生活质量之间的关系。

方法

本研究为横断面研究,纳入了 2020 年 5 月至 2021 年 5 月在中国 3 家医院癌症门诊接受靶向治疗的 536 例 NSCLC 皮肤不良反应患者。采用功能评估癌症治疗-表皮生长因子受体抑制剂 18、癌症患者自我管理评估量表和医学应对方式问卷等结构问卷收集数据。采用 Pearson 相关分析和多元线性回归算法,确定应对方式、自我管理与健康相关生活质量之间的关系。

结果

536 例接受靶向治疗的 NSCLC 皮肤不良反应患者的健康相关生活质量总分为(46±12.84)分。健康相关生活质量与自我管理呈正相关(r=0.785,P<0.01),与屈服(r= -0.718,P<0.01)、回避(r= -0.711,P<0.01)呈负相关,与应对方式(r=0.807,P<0.01)呈正相关。通过多元线性回归分析,我们确定了一些与健康相关生活质量显著相关的因素,包括年龄、教育水平、药物联合应用、Charlson 合并症指数、疾病分期、应对方式、屈服、症状管理、日常活动管理、心理和情绪管理、自我效能和自我管理(P<0.05)。

结论

接受靶向治疗的 NSCLC 皮肤不良反应患者的健康相关生活质量普遍较差。与健康相关生活质量状况相关的关键因素是年龄、教育水平、合并症、药物联合应用、疾病分期、自我管理和应对方式。

相似文献

1
The health-related quality of life of lung cancer patients with EGFR-TKI-related skin adverse drug reactions and its relationship with coping style and self-management.表皮生长因子受体酪氨酸激酶抑制剂相关皮肤不良反应肺癌患者的健康相关生活质量及其与应对方式和自我管理的关系。
Support Care Cancer. 2022 Dec;30(12):9889-9899. doi: 10.1007/s00520-022-07451-2. Epub 2022 Nov 19.
2
The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy.接受靶向 EGFR-TKI 治疗的非小细胞肺癌患者的药物使用素养与皮肤不良反应之间的关系。
BMC Cancer. 2022 May 3;22(1):491. doi: 10.1186/s12885-022-09599-w.
3
Home-based multidisciplinary interventions on skin adverse reactions in EGFR-TKI-treated patients with lung cancer: a protocol for a randomised controlled trial.基于家庭的多学科干预措施治疗肺癌 EGFR-TKI 治疗患者皮肤不良反应:一项随机对照试验方案。
BMJ Open. 2022 Nov 28;12(11):e063921. doi: 10.1136/bmjopen-2022-063921.
4
Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study.酪氨酸激酶抑制剂治疗对肺癌患者皮肤毒性及皮肤相关生活质量的影响:一项观察性研究。
Medicine (Baltimore). 2020 Jun 5;99(23):e20510. doi: 10.1097/MD.0000000000020510.
5
Psychological resilience and related influencing factors in postoperative non-small cell lung cancer patients: A cross-sectional study.术后非小细胞肺癌患者的心理弹性及其相关影响因素:一项横断面研究。
Psychooncology. 2020 Nov;29(11):1815-1822. doi: 10.1002/pon.5485. Epub 2020 Sep 28.
6
Relationships between self-efficacy, coping style and quality of work-life among nursing managers in China: A cross-sectional study.中国护理管理者自我效能感、应对方式与工作生活质量的关系:一项横断面研究。
J Nurs Manag. 2022 Oct;30(7):3236-3246. doi: 10.1111/jonm.13753. Epub 2022 Aug 17.
7
Influence of wellness education on first-line icotinib hydrochloride patients with stage IV non-small cell lung cancer and their family caregivers.健康宣教对一线盐酸埃克替尼治疗的IV期非小细胞肺癌患者及其家庭照顾者的影响
Curr Probl Cancer. 2018 May-Jun;42(3):358-366. doi: 10.1016/j.currproblcancer.2018.03.006. Epub 2018 Apr 11.
8
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体(EGFR)突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
9
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.一线化疗治疗成人局部晚期或转移性非小细胞肺癌的临床效果和成本效益:系统评价和经济评估。
Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310.
10
The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.因不良事件而更换表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗非小细胞肺癌的效果。
Asia Pac J Clin Oncol. 2020 Apr;16(2):e113-e117. doi: 10.1111/ajco.13103. Epub 2018 Dec 2.

引用本文的文献

1
Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team.表皮生长因子受体抑制剂相关皮肤毒性:日本药师主导的肿瘤皮肤病学研究团队对亚洲患者管理及可能的预防和治疗方法的综述
Int J Clin Oncol. 2025 Sep 1. doi: 10.1007/s10147-025-02868-1.
2
Experience and Needs of Immunotherapy for Lung Cancer Patients: A Meta-Synthesis of Qualitative Studies.肺癌患者免疫治疗的经验与需求:定性研究的元整合
Psychooncology. 2025 Jul;34(7):e70211. doi: 10.1002/pon.70211.
3
Latent profile analysis of self-management and its association with quality of life differences in patients with cancer treated with immune checkpoint inhibitors.

本文引用的文献

1
Correction to: Rationale and Design of a Telehealth Self-Management, Shared Care Intervention for Post-treatment Survivors of Lung and Colorectal Cancer.对《肺癌和结直肠癌治疗后幸存者远程医疗自我管理共享护理干预的基本原理与设计》的更正
J Cancer Educ. 2021 Apr;36(2):421. doi: 10.1007/s13187-021-01969-5.
2
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
3
Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer.
免疫检查点抑制剂治疗的癌症患者自我管理的潜在类别分析及其与生活质量差异的关联
Asia Pac J Oncol Nurs. 2025 Mar 13;12:100687. doi: 10.1016/j.apjon.2025.100687. eCollection 2025 Dec.
4
The mediating effects of coping strategies between symptom clusters and quality of life in lung cancer patients undergoing immunotherapy.接受免疫治疗的肺癌患者症状簇与生活质量之间应对策略的中介作用。
BMC Psychiatry. 2025 Apr 2;25(1):322. doi: 10.1186/s12888-025-06635-4.
5
The mediating effect of positive coping in the association between inner strength and demoralization in lung cancer chemotherapy patients.积极应对方式在肺癌化疗患者内在力量与士气低落关联中的中介作用
Support Care Cancer. 2025 Feb 24;33(3):216. doi: 10.1007/s00520-025-09185-3.
6
Health related quality of life and its influencing factors in Chinese patients with ocular tumors.中国眼部肿瘤患者的健康相关生活质量及其影响因素
Sci Rep. 2025 Feb 10;15(1):4927. doi: 10.1038/s41598-025-88747-1.
7
Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer.患者对酪氨酸激酶抑制剂治疗非小细胞肺癌相关治疗毒性及治疗药物监测的观点。
Ther Adv Med Oncol. 2024 Dec 7;16:17588359241303403. doi: 10.1177/17588359241303403. eCollection 2024.
8
How social support influences learned helplessness in lung cancer patients: the chain mediation role of individual resilience and self-efficacy.社会支持如何影响肺癌患者的习得性无助:个人复原力和自我效能感的链式中介作用
Front Psychol. 2024 Sep 5;15:1436495. doi: 10.3389/fpsyg.2024.1436495. eCollection 2024.
9
Investigating adherence to tyrosine kinase inhibitors in renal cancer.研究肾癌患者对酪氨酸激酶抑制剂的依从性。
J Oncol Pharm Pract. 2024 Jun 5:10781552241259354. doi: 10.1177/10781552241259354.
10
Pain experience of lung cancer patients during home recovery after surgery: A qualitative descriptive study.肺癌患者术后居家康复期的疼痛体验:一项定性描述性研究。
Cancer Med. 2023 Oct;12(19):20212-20223. doi: 10.1002/cam4.6616. Epub 2023 Oct 3.
米诺环素可预防和修复与阿法替尼相关的皮肤疾病,阿法替尼是一种表皮生长因子受体酪氨酸激酶抑制剂,用于治疗非小细胞肺癌。
BMC Cancer. 2020 Apr 6;20(1):279. doi: 10.1186/s12885-020-06797-2.
4
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.厄洛替尼对比吉西他滨/顺铂用于表皮生长因子受体突变阳性的晚期非小细胞肺癌中国患者:ENSURE 研究的交叉扩展和事后分析。
Lung Cancer. 2019 Apr;130:18-24. doi: 10.1016/j.lungcan.2019.01.016. Epub 2019 Jan 31.
5
Difficulties and challenges in the development of precision medicine.精准医学发展面临的困难与挑战。
Clin Genet. 2019 May;95(5):569-574. doi: 10.1111/cge.13511. Epub 2019 Feb 14.
6
Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.靶向抗癌疗法和免疫疗法引起的严重皮肤不良反应。
Cancer Manag Res. 2018 May 17;10:1259-1273. doi: 10.2147/CMAR.S163391. eCollection 2018.
7
Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients.靶向治疗引起的面部皮肤毒性:对癌症患者生活质量的影响。
Asia Pac J Oncol Nurs. 2018 Apr-Jun;5(2):172-177. doi: 10.4103/apjon.apjon_74_17.
8
Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents.靶向治疗:使用分子和免疫靶向药物对抗癌症。
Asia Pac J Oncol Nurs. 2018 Apr-Jun;5(2):137-155. doi: 10.4103/apjon.apjon_79_17.
9
Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.遗传多态性与肾细胞癌分子靶向治疗的不良反应相关。
Med Oncol. 2018 Jan 4;35(2):16. doi: 10.1007/s12032-017-1077-0.
10
Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study.无法治愈的肺癌女性的心理困扰和应对策略:一项定性研究。
Support Care Cancer. 2018 Mar;26(3):989-996. doi: 10.1007/s00520-017-3919-x. Epub 2017 Oct 10.